Advances in COVID-19 mRNA vaccine development
E Fang, X Liu, M Li, Z Zhang, L Song, B Zhu… - Signal transduction and …, 2022 - nature.com
To date, the coronavirus disease 2019 (COVID-19) caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) has determined 399,600,607 cases and 5,757,562 …
syndrome coronavirus 2 (SARS-CoV-2) has determined 399,600,607 cases and 5,757,562 …
The dawn of mRNA vaccines: The COVID-19 case
R Verbeke, I Lentacker, SC De Smedt… - Journal of Controlled …, 2021 - Elsevier
In less than one year since the outbreak of the COVID-19 pandemic, two mRNA-based
vaccines, BNT162b2 and mRNA-1273, were granted the first historic authorization for …
vaccines, BNT162b2 and mRNA-1273, were granted the first historic authorization for …
BNT162b vaccines protect rhesus macaques from SARS-CoV-2
AB Vogel, I Kanevsky, Y Che, KA Swanson, A Muik… - Nature, 2021 - nature.com
A safe and effective vaccine against COVID-19 is urgently needed in quantities that are
sufficient to immunize large populations. Here we report the preclinical development of two …
sufficient to immunize large populations. Here we report the preclinical development of two …
mRNA vaccines in the COVID-19 pandemic and beyond
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of coronavirus
disease 2019 (COVID-19), emerged in China in December 2019 and quickly spread around …
disease 2019 (COVID-19), emerged in China in December 2019 and quickly spread around …
[HTML][HTML] mRNA vaccines for COVID-19: what, why and how
JW Park, PNP Lagniton, Y Liu… - International journal of …, 2021 - ncbi.nlm.nih.gov
Abstract The Coronavirus disease-19 (COVID-19) pandemic, caused by severe acute
respiratory syndrome coronavirus-2 (SARS-CoV-2), has impacted human lives in the most …
respiratory syndrome coronavirus-2 (SARS-CoV-2), has impacted human lives in the most …
COVID-19 mRNA vaccines: Platforms and current developments
GT Szabó, AJ Mahiny, I Vlatkovic - Molecular Therapy, 2022 - cell.com
Since the first successful application of messenger ribonucleic acid (mRNA) as a vaccine
agent in a preclinical study nearly 30 years ago, numerous advances have been made in …
agent in a preclinical study nearly 30 years ago, numerous advances have been made in …
Covid‐19 vaccines and variants of concern: a review
I Hadj Hassine - Reviews in medical virology, 2022 - Wiley Online Library
Since the outbreak of coronavirus disease 2019 (Covid‐19) in December 2019, caused by
the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), the number of …
the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), the number of …
SARS-CoV-2 mRNA vaccines: immunological mechanism and beyond
To successfully protect against pathogen infection, a vaccine must elicit efficient adaptive
immunity, including B and T cell responses. While B cell responses are key, as they can …
immunity, including B and T cell responses. While B cell responses are key, as they can …
Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded …
Background Additional safe and efficacious vaccines are needed to control the COVID-19
pandemic. We aimed to analyse the efficacy and safety of the CVnCoV SARS-CoV-2 mRNA …
pandemic. We aimed to analyse the efficacy and safety of the CVnCoV SARS-CoV-2 mRNA …
Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine
Abstract The CVnCoV (CureVac) mRNA vaccine for severe acute respiratory syndrome
coronavirus-2 (SARS-CoV-2) was recently evaluated in a phase 2b/3 efficacy trial in …
coronavirus-2 (SARS-CoV-2) was recently evaluated in a phase 2b/3 efficacy trial in …